


Product Data Sheet

Tivozanib (AV-951)

Cat. No.:	A2251
CAS No.:	475108-18-0
Formula:	C22H19ClN4O5
M.Wt:	454.86
Synonyms:	
Target:	Tyrosine Kinase
Pathway:	VEGFR
Storage:	Store at -20°C



Solvent & Solubility

≥22.75 mg/mL in DMSO; insoluble in H₂O; ≥2.68 mg/mL in EtOH with gentle warming

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	Concentration			
	1 mM	2.1985 mL	10.9924 mL	21.9848 mL
	5 mM	0.4397 mL	2.1985 mL	4.3970 mL
	10 mM	0.2198 mL	1.0992 mL	2.1985 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

VEGFR inhibitor,potent and selective

IC₅₀ & Target

160 pM (VEGFR-2)

In Vitro

Cell Viability Assay

Cell Line: Human ovarian carcinoma cell lines, including A2780CP, OVCAR3 and SKOV3.

Preparation method: Soluble in DMSO >22.8mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

	Reacting conditions:	10µm, 48h
	Applications:	Combination of tivozanib with the EGFR(Epidermal Growth Factor Receptor)-directed therapies displayed synergistic activity on cell growth inhibition and induction of apoptosis, suggesting that anti-VEGFR(vascular endothelial growth factor receptor) -targeted approaches induced sensitisation to the EGFR-directed therapies.
In Vivo	Animal experiment	
	Dosage form:	1.5 mg OD for 3 weeks, oral administration
	Applications:	Tivozanib exhibit an inhibitory profile with high sensitivity for inhibition of VEGFR family members. Patients receiving tivozanib had a PFS(Progression free survival) of 12.7 months – the best PFS reported in a phase III trial with mRCC.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Momeny M1, Sabourinejad Z2,3, et al, Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep. 2017 Apr 6;7:45954. doi: 10.1038/srep45954.
- [2]. Grünwald V1, Merseburger AS2. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors – Is there more to come Eur J Cancer. 2013 Jul;49(11):2504-11. doi: 10.1016/j.ejca.2013.03.022. Epub 2013 Apr 16.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

